Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE5.5000
- TODAY'S CHANGE (%)0.1300 (2.4209%)
- Bid / Lots5.3700/ 9
- Ask / Lots5.5900/ 3
- Open / Previous Close5.4400 / 5.3700
- Day Range
- 52 Week Range
- Volume509,722
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 2784 | 5.44 |
| 09:34 ET | 7521 | 5.395 |
| 09:36 ET | 1876 | 5.48 |
| 09:38 ET | 3131 | 5.53 |
| 09:39 ET | 200 | 5.5 |
| 09:41 ET | 200 | 5.51 |
| 09:43 ET | 1707 | 5.51 |
| 09:45 ET | 13511 | 5.58 |
| 09:48 ET | 11760 | 5.5405 |
| 09:50 ET | 150 | 5.5444 |
| 09:52 ET | 6119 | 5.53 |
| 09:54 ET | 21662 | 5.57 |
| 09:56 ET | 2030 | 5.54 |
| 09:57 ET | 7100 | 5.49 |
| 09:59 ET | 300 | 5.49 |
| 10:01 ET | 3249 | 5.495 |
| 10:03 ET | 624 | 5.5 |
| 10:06 ET | 1100 | 5.5 |
| 10:08 ET | 4218 | 5.5 |
| 10:10 ET | 1448 | 5.51 |
| 10:12 ET | 11805 | 5.51 |
| 10:14 ET | 100 | 5.49 |
| 10:15 ET | 100 | 5.495 |
| 10:17 ET | 8744 | 5.48 |
| 10:19 ET | 430 | 5.485 |
| 10:21 ET | 822 | 5.5 |
| 10:24 ET | 1200 | 5.5 |
| 10:28 ET | 200 | 5.5 |
| 10:30 ET | 925 | 5.525 |
| 10:32 ET | 1528 | 5.5 |
| 10:33 ET | 300 | 5.5 |
| 10:35 ET | 498 | 5.51 |
| 10:37 ET | 917 | 5.52 |
| 10:39 ET | 1117 | 5.52 |
| 10:42 ET | 1370 | 5.5 |
| 10:44 ET | 608 | 5.51 |
| 10:46 ET | 901 | 5.54 |
| 10:48 ET | 1326 | 5.54 |
| 10:50 ET | 500 | 5.53 |
| 10:51 ET | 500 | 5.53 |
| 10:53 ET | 5611 | 5.54 |
| 10:55 ET | 32859 | 5.56 |
| 10:57 ET | 2449 | 5.58 |
| 11:00 ET | 3354 | 5.625 |
| 11:02 ET | 825 | 5.625 |
| 11:06 ET | 1117 | 5.63 |
| 11:08 ET | 5182 | 5.64 |
| 11:09 ET | 1877 | 5.64 |
| 11:11 ET | 400 | 5.64 |
| 11:13 ET | 3402 | 5.63 |
| 11:15 ET | 545 | 5.63 |
| 11:18 ET | 2147 | 5.67 |
| 11:22 ET | 900 | 5.62 |
| 11:24 ET | 600 | 5.635 |
| 11:26 ET | 1018 | 5.61 |
| 11:27 ET | 2800 | 5.5998 |
| 11:29 ET | 100 | 5.6 |
| 11:31 ET | 230 | 5.6 |
| 11:33 ET | 100 | 5.6 |
| 11:36 ET | 400 | 5.61 |
| 11:38 ET | 800 | 5.6 |
| 11:40 ET | 100 | 5.585 |
| 11:42 ET | 402 | 5.595 |
| 11:44 ET | 552 | 5.61 |
| 11:45 ET | 800 | 5.595 |
| 11:47 ET | 2593 | 5.6 |
| 11:49 ET | 1005 | 5.59 |
| 11:51 ET | 10540 | 5.575 |
| 11:56 ET | 200 | 5.585 |
| 11:58 ET | 400 | 5.59 |
| 12:02 ET | 400 | 5.59 |
| 12:03 ET | 633 | 5.59 |
| 12:07 ET | 400 | 5.59 |
| 12:09 ET | 200 | 5.591 |
| 12:12 ET | 400 | 5.58 |
| 12:14 ET | 100 | 5.57 |
| 12:16 ET | 400 | 5.55 |
| 12:18 ET | 100 | 5.545 |
| 12:20 ET | 100 | 5.545 |
| 12:21 ET | 587 | 5.55 |
| 12:25 ET | 200 | 5.56 |
| 12:27 ET | 1491 | 5.55 |
| 12:30 ET | 5007 | 5.57 |
| 12:34 ET | 573 | 5.56 |
| 12:36 ET | 835 | 5.57 |
| 12:38 ET | 300 | 5.57 |
| 12:39 ET | 600 | 5.58 |
| 12:41 ET | 794 | 5.58 |
| 12:43 ET | 100 | 5.575 |
| 12:45 ET | 600 | 5.57 |
| 12:48 ET | 100 | 5.57 |
| 12:50 ET | 200 | 5.575 |
| 12:52 ET | 100 | 5.57 |
| 12:54 ET | 633 | 5.58 |
| 12:56 ET | 2033 | 5.56 |
| 01:01 ET | 1100 | 5.555 |
| 01:03 ET | 705 | 5.57 |
| 01:06 ET | 100 | 5.565 |
| 01:08 ET | 4218 | 5.54 |
| 01:10 ET | 100 | 5.53 |
| 01:12 ET | 400 | 5.53 |
| 01:14 ET | 415 | 5.54 |
| 01:15 ET | 400 | 5.55 |
| 01:17 ET | 3655 | 5.54 |
| 01:19 ET | 100 | 5.55 |
| 01:21 ET | 715 | 5.54 |
| 01:24 ET | 200 | 5.545 |
| 01:26 ET | 300 | 5.55 |
| 01:28 ET | 100 | 5.555 |
| 01:30 ET | 407 | 5.56 |
| 01:32 ET | 800 | 5.56 |
| 01:33 ET | 100 | 5.56 |
| 01:35 ET | 200 | 5.55 |
| 01:39 ET | 782 | 5.535 |
| 01:42 ET | 500 | 5.53 |
| 01:44 ET | 1200 | 5.525 |
| 01:46 ET | 400 | 5.525 |
| 01:48 ET | 100 | 5.53 |
| 01:50 ET | 1205 | 5.535 |
| 01:51 ET | 100 | 5.53 |
| 01:55 ET | 9700 | 5.535 |
| 01:57 ET | 1700 | 5.535 |
| 02:02 ET | 138 | 5.5389 |
| 02:04 ET | 200 | 5.53 |
| 02:06 ET | 100 | 5.54 |
| 02:08 ET | 100 | 5.53 |
| 02:09 ET | 2141 | 5.515 |
| 02:11 ET | 200 | 5.505 |
| 02:13 ET | 600 | 5.51 |
| 02:15 ET | 807 | 5.51 |
| 02:20 ET | 5840 | 5.48 |
| 02:22 ET | 500 | 5.48 |
| 02:24 ET | 1488 | 5.46 |
| 02:27 ET | 1575 | 5.43 |
| 02:29 ET | 16950 | 5.48 |
| 02:31 ET | 7781 | 5.51 |
| 02:33 ET | 9387 | 5.52 |
| 02:36 ET | 4323 | 5.52 |
| 02:38 ET | 1410 | 5.495 |
| 02:40 ET | 117 | 5.48 |
| 02:42 ET | 100 | 5.49 |
| 02:45 ET | 1063 | 5.485 |
| 02:47 ET | 701 | 5.495 |
| 02:49 ET | 100 | 5.495 |
| 02:54 ET | 100 | 5.495 |
| 02:56 ET | 1000 | 5.4915 |
| 02:58 ET | 390 | 5.5 |
| 03:03 ET | 880 | 5.49 |
| 03:07 ET | 100 | 5.495 |
| 03:09 ET | 1624 | 5.47 |
| 03:12 ET | 836 | 5.48 |
| 03:14 ET | 1003 | 5.46 |
| 03:16 ET | 207 | 5.47 |
| 03:20 ET | 400 | 5.47 |
| 03:21 ET | 300 | 5.475 |
| 03:25 ET | 200 | 5.475 |
| 03:27 ET | 1950 | 5.48 |
| 03:30 ET | 400 | 5.48 |
| 03:32 ET | 1203 | 5.48 |
| 03:34 ET | 200 | 5.475 |
| 03:36 ET | 100 | 5.465 |
| 03:38 ET | 100 | 5.465 |
| 03:39 ET | 100 | 5.465 |
| 03:41 ET | 825 | 5.47 |
| 03:43 ET | 2065 | 5.46 |
| 03:45 ET | 100 | 5.465 |
| 03:48 ET | 3256 | 5.49 |
| 03:50 ET | 2163 | 5.49 |
| 03:52 ET | 1317 | 5.492 |
| 03:54 ET | 338 | 5.495 |
| 03:56 ET | 428 | 5.495 |
| 03:57 ET | 5042 | 5.505 |
| 03:59 ET | 43111 | 5.5 |
Sep 5, 2024
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26(th) Annual Global Investment Conference, from 7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
7:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 358.3M | -8.6x | --- |
Nautilus Biotechnology Inc | 363.7M | -5.2x | --- |
Black Diamond Therapeutics Inc | 349.8M | -2.7x | --- |
Monte Rosa Therapeutics Inc | 372.9M | -2.3x | --- |
Jasper Therapeutics Inc | 343.6M | -3.7x | --- |
Alto Neuroscience Inc | 374.0M | --- | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Principal Financial Officer and Principal Accounting Officer
- Michael Alfieri
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $358.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.43 |
EPS | $-0.64 |
Book Value | $2.02 |
P/E Ratio | -8.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
